A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT06024746

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06024746
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, Canada, China, India, Spain, Sri Lanka, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06024746. Randomized; no masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Acronym
CONFIRMATION
Condition
Heart Failure
Intervention (Drug)
Finerenone
Intervention (Drug)
Empagliflozin
Lead sponsor
Colorado Prevention Center (class: other)
Collaborator
Saint Luke's Mid America Heart Institute (class: not stated)
Collaborator
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma (class: industry)

Record details

Record id
cardio:ct-nct06024746
Content hash
0c85a31c09b62f3dd471cd8b6c7dd3ad8182bc0aa7909d1e9ed8ca13934ba3dd